Mark Gunby, DO
Geriatric Medicine · Saint Louis, MONPI 1699886309
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $793 and has fallen 92.3% since, to $61 in 2024.
Across 78 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$263
- GSK$191
- Novo Nordisk$121
- Stryker$114
- Amgen$81
- Johnson & Johnson$72
- plus $397 from 14 others
What the payments were for
- Food & beverage$1,238100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $263 |
| GSK | 18 | $191 |
| Novo Nordisk | 8 | $121 |
| Stryker | 1 | $114 |
| Amgen | 4 | $81 |
| Johnson & Johnson | 4 | $72 |
| Amarin Pharma, Inc. | 4 | $68 |
| Novartis | 4 | $62 |
| AbbVie(2 entities) | 2 | $52 |
| Lilly USA, LLC | 3 | $40 |
| Boehringer Ingelheim | 2 | $33 |
| Abbott | 2 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| AstraZeneca | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,239 in reported general payments places this provider in the 70th percentile of 76 geriatric medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 314 | $251,359 |
| JardianceEmpagliflozin | 114 | $132,225 |
| OzempicSemaglutide | 78 | $91,498 |
| XareltoRivaroxaban | 95 | $85,603 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $43,030 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 145 | $39,876 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 54 | $27,840 |
| JanuviaSitagliptin Phosphate | 24 | $27,531 |
| MounjaroTirzepatide | 29 | $25,815 |
| MyrbetriqMirabegron | 17 | $13,812 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $13,413 |
| TradjentaLinagliptin | 16 | $12,598 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $8,394 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $8,076 |
| Atorvastatin Calcium | 851 | $7,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $263 | $251,359314 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $33 | $153,217142 claims |
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Breo Ellipta | $191 | $124,158285 claims |
| Novo NordiskOzempic | $121 | $91,49878 claims |
| Johnson & JohnsonXarelto | $72 | $85,60395 claims |
| Lilly USA, LLCMounjaro | $40 | $25,81529 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $13,81217 claims |
| AstraZenecaSymbicort | $12 | $7,17917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 76 geriatric medicine providers in Missouri.
Other geriatric medicine in Saint Louis
- Angela SanfordSaint Louis$15K
- Ellen BinderSaint Louis$4K
- Poonam JainSaint Louis$4K
- Uchenna OgbuokiriSaint Louis$3K
- Charles CreceliusSaint Louis$3K
- Seema IyerSaint Louis$2K
- Hanish Sampath KumarSaint Louis$2K
- Richard OneillSaint Louis$1K
- David CarrSaint Louis$1K
- Susan ReedsSaint Louis$725
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.